转移性胃癌-话题@MedSci - williamhill asia

#转移性胃癌#

17篇内容 | 1123人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1735301, encodeId=3c611e35301ce, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, objectTitle=ESMO 2022：Trastuzumab Deruxtecan在转移性胃癌/GEJ癌中维持临床获益（DESTINY-Gastric02研究）, objectType=article, longId=739074, objectId=6781e3907456, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6781e3907456, replyNumber=0, likeNumber=62, createdTime=2023-03-24, rootId=0, userName=limedical1985, userId=7e6333886015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6781e3907456, moduleTitle=ESMO 2022：Trastuzumab Deruxtecan在转移性胃癌/GEJ癌中维持临床获益（DESTINY-Gastric02研究）, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=6781e3907456)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2130450, encodeId=585d213045012, content=<a href='/topic/show?id=9b41614554a' target=_blank style='color:#2F92EE;'>#李进#</a>教授：<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a><a href='/topic/show?id=d3c65861e2f' target=_blank style='color:#2F92EE;'>#新药#</a>进展, objectTitle=CSCO 2023 | 李进教授：转移性胃癌新药进展及威廉亚洲博彩公司更新要点, objectType=article, longId=768269, objectId=6b4be68269b6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20230411/5a2024f42a9e47b9b7ad9d60525d82f5.jpg, objectUrl=/article/show_article.do?id=6b4be68269b6, replyNumber=0, likeNumber=96, createdTime=2023-05-06, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=6b4be68269b6, moduleTitle=CSCO 2023 | 李进教授：转移性胃癌新药进展及威廉亚洲博彩公司更新要点, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=6b4be68269b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1735300, encodeId=e21c1e3530055, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, objectTitle=BMC Cancer：西方真实世界数据为免疫检查点抑制剂在经治转移性胃癌患者的疗效再添证据, objectType=article, longId=294051, objectId=55f229405108, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55f229405108, replyNumber=0, likeNumber=79, createdTime=2022-11-07, rootId=0, userName=limedical1985, userId=7e6333886015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55f229405108, moduleTitle=BMC Cancer：西方真实世界数据为免疫检查点抑制剂在经治转移性胃癌患者的疗效再添证据, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=55f229405108)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1735298, encodeId=87fb1e352982b, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, objectTitle=Front Oncol：信迪利单抗（Sintilimab）二线或以上治疗晚期或转移性胃癌疗效的回顾性研究, objectType=article, longId=217565, objectId=527e21e56566, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=527e21e56566, replyNumber=0, likeNumber=82, createdTime=2022-02-05, rootId=0, userName=limedical1985, userId=7e6333886015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=527e21e56566, moduleTitle=Front Oncol：信迪利单抗（Sintilimab）二线或以上治疗晚期或转移性胃癌疗效的回顾性研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=527e21e56566)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1735299, encodeId=3cd01e35299e2, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, objectTitle=BMC Cancer：多中心数据探索nivolumab治疗经治转移性胃癌患者获益的临床预后因素, objectType=article, longId=293706, objectId=27d9293e064d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27d9293e064d, replyNumber=0, likeNumber=63, createdTime=2022-05-25, rootId=0, userName=limedical1985, userId=7e6333886015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27d9293e064d, moduleTitle=BMC Cancer：多中心数据探索nivolumab治疗经治转移性胃癌患者获益的临床预后因素, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=27d9293e064d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1735297, encodeId=cd281e3529769, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, objectTitle=JCO：HER2在转移性胃癌中的表达及其对生存率的影响, objectType=article, longId=209151, objectId=483d20915154, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=483d20915154, replyNumber=0, likeNumber=73, createdTime=2022-03-11, rootId=0, userName=limedical1985, userId=7e6333886015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=483d20915154, moduleTitle=JCO：HER2在转移性胃癌中的表达及其对生存率的影响, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=483d20915154)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1735296, encodeId=47041e35296c9, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, objectTitle=JCO：北大肿瘤医院3期试验揭示多科室联合治疗转移性胃癌的临床获益, objectType=article, longId=205673, objectId=6fbf2056e3fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fbf2056e3fc, replyNumber=0, likeNumber=73, createdTime=2021-09-20, rootId=0, userName=limedical1985, userId=7e6333886015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fbf2056e3fc, moduleTitle=JCO：北大肿瘤医院3期试验揭示多科室联合治疗转移性胃癌的临床获益, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=6fbf2056e3fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1735295, encodeId=57281e3529562, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, objectTitle=Clin Cancer Res：二代紫杉烷卡巴他赛治疗转移性胃癌的疗效, objectType=article, longId=200858, objectId=da7d20085840, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da7d20085840, replyNumber=0, likeNumber=70, createdTime=2020-12-27, rootId=0, userName=limedical1985, userId=7e6333886015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da7d20085840, moduleTitle=Clin Cancer Res：二代紫杉烷卡巴他赛治疗转移性胃癌的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=da7d20085840)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1735294, encodeId=34a21e35294ab, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, objectTitle=FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌, objectType=article, longId=194130, objectId=0b9d19413073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b9d19413073, replyNumber=0, likeNumber=67, createdTime=2020-06-12, rootId=0, userName=limedical1985, userId=7e6333886015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b9d19413073, moduleTitle=FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0b9d19413073)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1735291, encodeId=89731e3529166, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, objectTitle=PD-1单抗三线治疗转移性胃癌，推荐等级“更上一层楼”, objectType=article, longId=166820, objectId=65e916682030, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65e916682030, replyNumber=0, likeNumber=68, createdTime=2019-06-02, rootId=0, userName=limedical1985, userId=7e6333886015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65e916682030, moduleTitle=PD-1单抗三线治疗转移性胃癌，推荐等级“更上一层楼”, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=65e916682030)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1735293, encodeId=ef0b1e352939f, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, objectTitle=抗体药物偶联物Enhertu达到HER2阳性转移性胃癌注册研究的主要终点, objectType=article, longId=186821, objectId=44e318682186, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44e318682186, replyNumber=0, likeNumber=53, createdTime=2020-04-26, rootId=0, userName=limedical1985, userId=7e6333886015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44e318682186, moduleTitle=抗体药物偶联物Enhertu达到HER2阳性转移性胃癌注册研究的主要终点, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=44e318682186)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1735292, encodeId=14f81e352926c, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, objectTitle=Gastric Cancer：低蛋白血症可以预测转移性胃癌患者的静脉血栓栓塞风险, objectType=article, longId=179120, objectId=29d01e91205f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29d01e91205f, replyNumber=0, likeNumber=59, createdTime=2020-07-08, rootId=0, userName=limedical1985, userId=7e6333886015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29d01e91205f, moduleTitle=Gastric Cancer：低蛋白血症可以预测转移性胃癌患者的静脉血栓栓塞风险, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=29d01e91205f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1735289, encodeId=a3c11e352892f, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, objectTitle=Lancet oncol：顺铂+卡培他滨联合化疗方案添加雷莫芦单抗并不能延长转移性胃癌患者的无进展存活期, objectType=article, longId=159661, objectId=f84d15966103, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f84d15966103, replyNumber=0, likeNumber=74, createdTime=2019-05-16, rootId=0, userName=limedical1985, userId=7e6333886015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f84d15966103, moduleTitle=Lancet oncol：顺铂+卡培他滨联合化疗方案添加雷莫芦单抗并不能延长转移性胃癌患者的无进展存活期, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f84d15966103)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1735290, encodeId=083e1e35290e0, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, objectTitle=免疫治疗或成为晚期转移性胃癌治疗重要选择, objectType=article, longId=166060, objectId=ee7616606088, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee7616606088, replyNumber=0, likeNumber=66, createdTime=2019-09-30, rootId=0, userName=limedical1985, userId=7e6333886015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee7616606088, moduleTitle=免疫治疗或成为晚期转移性胃癌治疗重要选择, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ee7616606088)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1735288, encodeId=85c61e35288a4, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, objectTitle=GUT：HER2阳性转移性胃癌患者曲妥珠单抗耐药机制研究进展, objectType=article, longId=150583, objectId=c84815058345, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c84815058345, replyNumber=0, likeNumber=80, createdTime=2019-04-16, rootId=0, userName=limedical1985, userId=7e6333886015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c84815058345, moduleTitle=GUT：HER2阳性转移性胃癌患者曲妥珠单抗耐药机制研究进展, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=c84815058345)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1735287, encodeId=c71f1e352876a, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, objectTitle=CLIN CANCER RES：HER-2阳性转移性胃癌曲妥珠单抗原发耐药的生物学标志, objectType=article, longId=131749, objectId=776a131e495c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=776a131e495c, replyNumber=0, likeNumber=78, createdTime=2018-10-27, rootId=0, userName=limedical1985, userId=7e6333886015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=776a131e495c, moduleTitle=CLIN CANCER RES：HER-2阳性转移性胃癌曲妥珠单抗原发耐药的生物学标志, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=776a131e495c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1735286, encodeId=5ded1e35286d7, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, objectTitle=GCS 2014：Ramucirumab联合治疗可改善转移性胃癌总生存, objectType=article, longId=29826, objectId=512a298266a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=512a298266a, replyNumber=0, likeNumber=58, createdTime=2014-08-11, rootId=0, userName=limedical1985, userId=7e6333886015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=512a298266a, moduleTitle=GCS 2014：Ramucirumab联合治疗可改善转移性胃癌总生存, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=512a298266a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

转移性胃癌

2020-05-29

limedical1985 (审核中...)

前往app查看评论内容

#转移性胃癌#

ESMO 2022：Trastuzumab Deruxtecan在转移性胃癌/GEJ癌中维持临床获益（DESTINY-Gastric02研究）

2023-03-24

侠胆医心 (审核中...)

前往app查看评论内容

#李进#教授：#转移性胃癌##新药#进展

CSCO 2023 | 李进教授：转移性胃癌新药进展及威廉亚洲博彩公司更新要点

2023-05-06发表于上海

limedical1985 (审核中...)

前往app查看评论内容

#转移性胃癌#

BMC Cancer：西方真实世界数据为免疫检查点抑制剂在经治转移性胃癌患者的疗效再添证据

2022-11-07

limedical1985 (审核中...)

前往app查看评论内容

#转移性胃癌#

Front Oncol：信迪利单抗（Sintilimab）二线或以上治疗晚期或转移性胃癌疗效的回顾性研究

2022-02-05

limedical1985 (审核中...)

前往app查看评论内容

#转移性胃癌#

BMC Cancer：多中心数据探索nivolumab治疗经治转移性胃癌患者获益的临床预后因素

2022-05-25

limedical1985 (审核中...)

前往app查看评论内容

#转移性胃癌#

JCO：HER2在转移性胃癌中的表达及其对生存率的影响

2022-03-11

limedical1985 (审核中...)

前往app查看评论内容

#转移性胃癌#

JCO：北大肿瘤医院3期试验揭示多科室联合治疗转移性胃癌的临床获益

2021-09-20

limedical1985 (审核中...)

前往app查看评论内容

#转移性胃癌#

Clin Cancer Res：二代紫杉烷卡巴他赛治疗转移性胃癌的疗效

2020-12-27

limedical1985 (审核中...)

前往app查看评论内容

#转移性胃癌#

FDA授予靶向HER2的抗体药物偶联物ENHERTU突破性疗法称号，以治疗HER2阳性转移性胃癌

2020-06-12

limedical1985 (审核中...)

前往app查看评论内容

#转移性胃癌#

PD-1单抗三线治疗转移性胃癌，推荐等级“更上一层楼”

2019-06-02

limedical1985 (审核中...)

前往app查看评论内容

#转移性胃癌#

抗体药物偶联物Enhertu达到HER2阳性转移性胃癌注册研究的主要终点

2020-04-26

limedical1985 (审核中...)

前往app查看评论内容

#转移性胃癌#

Gastric Cancer：低蛋白血症可以预测转移性胃癌患者的静脉血栓栓塞风险

2020-07-08

limedical1985 (审核中...)

前往app查看评论内容

#转移性胃癌#

Lancet oncol：顺铂+卡培他滨联合化疗方案添加雷莫芦单抗并不能延长转移性胃癌患者的无进展存活期

2019-05-16

limedical1985 (审核中...)

前往app查看评论内容

#转移性胃癌#

免疫治疗或成为晚期转移性胃癌治疗重要选择

2019-09-30

limedical1985 (审核中...)

前往app查看评论内容

#转移性胃癌#

GUT：HER2阳性转移性胃癌患者曲妥珠单抗耐药机制研究进展

2019-04-16

limedical1985 (审核中...)

前往app查看评论内容

#转移性胃癌#

CLIN CANCER RES：HER-2阳性转移性胃癌曲妥珠单抗原发耐药的生物学标志

2018-10-27

limedical1985 (审核中...)

前往app查看评论内容

#转移性胃癌#

GCS 2014：Ramucirumab联合治疗可改善转移性胃癌总生存

2014-08-11

科室
- - 订阅+
  - 更多科室
工具
服务